NSE: CAPLIPOINT · 18 November 2026
- Caplin Point Laboratories has fallen 11.55% over 2 trading sessions; today's move is -7.20%.
- Caplin Point Laboratories Limited informed the exchange that the US FDA inspection at the facility of its subsidiary, Caplin Steriles Limited, has been classified as Official Action Indicated (OAI). The update follows an unannounced inspection previously completed at the facility.
- Trading volume was 6.69 times the 20-day average daily volume.
Caplin Point Laboratories share price: 11.55% decline over 2 trading sessions
Caplin Point Laboratories Ltd. shares fell 7.20% today, closing at ₹2085.30 after touching an intraday high of ₹2239.60 and a low of ₹2072.00.
While the broader healthcare sector benchmark, Nifty Pharma, managed a modest gain of 0.15%, the broader market index Nifty declined by 0.63%. Caplin Point's sharp decline contributed to an extended short-term correction, bringing its 5-day return down to -17.64% and its 20-day return to -8.10%.
Recent corporate developments show that the United States Food and Drug Administration classified an inspection at the facility of Caplin Steriles Limited, a subsidiary of the company, as Official Action Indicated on November 17, 2026.
7.10 lakh shares traded by 18 November 2026 · 03:30 PM IST. This compares with a 20-day average daily volume of 1.06 lakh shares (6.69 times). The five-day average daily volume was 1.94 lakh shares. Separately, the NSE report for 18 November 2026 showed 1.86 lakh shares delivered, representing 26.18% of that day’s traded volume. The same report recorded 63,565 trades.
The stock's sharp decline coincides with elevated cash trading volumes and follows the recent US FDA OAI classification for its subsidiary facility. Although no single catalyst is explicitly proven to have caused today's exact drop, the price action aligns with ongoing correction after recent weakness.
Latest Company Developments
Caplin Point Laboratories Limited informed the exchange that the US FDA inspection at the facility of its subsidiary, Caplin Steriles Limited, has been classified as Official Action Indicated (OAI). The update follows an unannounced inspection previously completed at the facility.
An OAI classification from regulatory authorities can impact timelines for pending product approvals and warrants close monitoring regarding remediation measures.
The company submitted its unaudited financial results for the quarter and half year ended September 30, 2026, to stock exchanges. Management subsequently hosted an earnings audio conference call and released an investor presentation detailing operating performance.
Quarterly earnings and management commentary provide core baseline metrics for evaluating revenue growth, operating margins, and export execution.
Classification of US FDA Inspection at the facility of Caplin Steriles Limited (Company's Subsidiary) as OAI
Caplin Point Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Significant increase in volume has been observed in Caplin Point Laboratories Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Caplin Point Laboratories Limited has submitted their response.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 1.64% on 30 September 2026. This compares with 2.03% on 30 June 2026, a change of -0.39 percentage points.
The filing reported 20 MF/UTI holders.
What to Watch Next
- Official updates and remediation responses regarding the US FDA OAI classification for Caplin Steriles Limited
- Cash trading volume and delivery percentage trends relative to the 20-day average
- Management commentary on US ANDA filings and regulatory clearance timelines
- Broader Nifty Pharma sector price direction and relative strength
Other Dated Coverage
More Caplin Point Laboratories news and dated analysis →
Frequently Asked Questions
What is the latest Caplin Point Laboratories company news?
Caplin Point Laboratories Limited informed the exchange that the US FDA inspection at the facility of its subsidiary, Caplin Steriles Limited, has been classified as Official Action Indicated (OAI). The update follows an unannounced inspection previously completed at the facility.
How strong was Caplin Point Laboratories’s trading volume?
7.10 lakh shares traded, 6.69 times the 20-day average daily volume. The price and volume data are dated 18 November 2026 · 03:30 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.
